EDQM issues CEP Certificate for Pantoprazole Sodium Sesquihydrate
IOLCP receives CEP certificate from EDQM for its API product Pantoprazole Sodium Sesquihydrate Process -III, used in drugs for treating GERD and other conditions.
The certification is likely to have a moderate impact on the company's business, potentially improving market access and product credibility.
The announcement indicates a positive development for the company as it has received a certificate for its API product.
* The European Directorate for the Quality of Medicines & Health Care (EDQM) has issued a Certificate of Suitability for the company’s API product “Pantoprazole Sodium Sesquihydrate Process -III” on 14th October 2025. * Pantoprazole sodium is a proton pump inhibitor (PPI) used to treat conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.